Almost 17 million people worldwide experience a firsttime stroke each year 1 , which is equivalent to one new stroke every 2 seconds. Mortality associated with stroke is declining 2 , but in the UK alone, over 1 million people live with the consequences of stroke; over one-third of these people depend on others for their care. The epidemiological shift of stroke disease burden towards long-term conditions means that these numbers will continue to rise 3 . Often, the decline in functional abilities that takes place in many patients 4 goes unrecognized, so, unsurprisingly, the overall economic burden of stroke is high (estimated at over UK£9 billion a year in the UK). The fact that stroke is both a chronic and a progressive condition should influence priorities in medical research, but funding for research into stroke, and stroke recovery in particular, lags far behind research funding for cancer, coronary heart disease and dementia 5 . Improvement of recovery and long-term outcomes is an urgent clinical and scientific goal, but success is slow to materialize.
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Care in the hyperacute and acute period after stroke has improved dramatically over the past two decades, but our attention must now turn to treatments that actively promote recovery. One reason for optimism is that work in animal models points to a timelimited period of heightened plasticity after focal brain injury. However, achieving the best possible outcomes in patients after stroke requires two key challenges to be addressed. The first is how to take advantage of this critical period through the optimal timing, intensity, amount and even type of behavioural training that makes up neurorehabilitation. This question has been discussed elsewhere but, in brief, studies support the use of intense training that focuses on the reduction of impairment in the first few weeks and months poststroke, to take advantage of biological repair mechanisms 6 . The second challenge, and the focus of this Review, is how to augment the biological mechanisms of poststroke plasticity to enhance or prolong the effects of behavioural training in patients after a stroke. The translational nature of this question is important, because although work in preclinical animal models has been pivotal in highlighting the biological basis of recovery, virtually no benefit has yet been observed for humans. I will discuss the possible reasons for this lack of benefit and the prospects for developing a mechanistic understanding of poststroke plasticity in humans. Particularly exciting prospects exist for the development of human biomarkers that provide an appropriate intermediate level of mechanistic description with which to reconcile what we know about recovery on the basis of preclinical studies and human studies.
Biomarkers
Indicators of disease state that can be used clinically as a measure of underlying molecular or cellular processes that might be difficult to measure directly in humans, and can be used to predict recovery or treatment response.
Proportional recovery rule
The amount of function regained after stroke is a proportion of the initial deficit. For example, by 3 months, patients will regain ~70% of the upper limb motor function that had been lost on day 3 after stroke.
Hemispatial neglect
Reduced awareness of stimuli on one side of space, even though sensory loss might be absent.
Spontaneous biological recovery
Recovery occurring in the first few weeks and months after stroke, attributable to increased poststroke plasticity mechanisms; recovery is rapid, occurs at the level of impairment and generalizes beyond the tasks that are used in poststroke training, compared with improvements seen in the chronic phase of stroke.
Recovery after stroke is proportional A starting point for determining the biological basis of recovery in patients after a stroke is to ask why some patients fail to recover. Stroke is one of the most common causes of physical disability worldwide and ~80% of stroke survivors experience impairment of movement on one side of the body 7 . Hand and arm impairment in particular is often persistent, disabling 8 and a major contributor to reduced quality of life. In one study, only 38% of patients who presented with an initially paralysed upper limb regained some dexterity by 6 months 9 , and twothirds of patients perceived that loss of arm function was still a major problem after 4 years 10 . These studies and many others clearly demonstrate that recovery is variable and difficult to predict. Factors associated with poor outcomes include right hemisphere damage, somatosensory deficit, visual inattention, homonymous hemianopia and urinary incontinence 9, 11 . However, the dominant factor for predicting long-term upper limb outcome is initial severity of motor impairment 11 . Additional factors that have independent predictive power over and above their association with this initial severity have not been identified.
The ability of initial severity to predict upper limb recovery was first quantified as the proportional recovery rule 12 . When applied to real clinical data, two key findings (FIG. 1) provide challenges, but also opportunities, for the field. The first is that initial upper limb impairment predicts later upper limb outcome extremely accurately in patients who present with mild to moderate impairment. This result is disconcerting to those involved in poststroke neurorehabilitation because it implies that any variability in the dose of rehabilitation delivered in the first 3 months exerts no substantial effect on a patient's level of motor impairment. The second key finding is that among patients who present with high severity, recovery is proportional to the initial severity in approximately half, whereas no substantial recovery is seen in the other half (FIG. 1) . Importantly, this finding tells us that the causes of initial impairment are probably independent from the biological factors that are important for the subsequent recovery process. This inter pretation provides an opportunity, because factors that are important for recovery might represent targets for novel therapeutics that aim to optimize the biological factors that maximize the effects of behavioural training.
The proportional recovery rule has been confirmed in the motor domain several times [12] [13] [14] [15] and suggests two clear clinical questions. First, how can we help patients with stroke to regain more than 70% of lost function, and second, how can we turn poor recoverers into proportional recoverers? The answers to these questions will dramatically change our approaches to the promotion of recovery after stroke. Evidence also suggests that proportional recovery applies to nonmotor domains, such as language 16 and hemispatial neglect 17 , so this striking clinical phenomenon provides a novel and important model for investigating potentially modifiable biological factors that are necessary for maximizing recovery of function after stroke in humans, as well as currently nonmodifiable factors that will help to make accurate predictions of long-term outcome.
Some patients experience poor recovery after stroke whereas others who are clinically indistinguishable have good recovery. The differences in these two groups manifest in the first few days and weeks after stroke. During this time there might (or might not) be a rapid generalized improvement in function that is in contrast to the modest gains made in the chronic phase 18 . Decades of work in animal models clearly shows that focal brain damage is followed by a window of opportunity in which behavioural training has its maximum effect. This early poststroke phase has been described as a period of spontaneous biological recovery. Early evidence of this critical period for recovery-related training was provided by Biernaskie and colleagues 19 who found that rats that commenced motor training of the affected forelimb starting at 30 days poststroke exhibited little improvement when compared with those whose treatment commenced earlier, at 5-14 days poststroke. The causal role of the lesion itself in initiating spontaneous biological recovery was illustrated further by Zeiler and colleagues 20 , who showed that intensive reach training was not able to promote full recovery in a mouse when commenced 7 days after stroke. However, when a second stroke was induced in the same animal and training was commenced 2 days later (presumably within the critical period), recovery was substantially improved, and performance levels approached those seen before either stroke. Clearly, focal brain damage sets in motion a series of biological events that, when combined with appropriate type and intensity of behavioural training 6 , can support dramatic recovery.
Structural plasticity after stroke A substantial amount of work has been undertaken in animal models to define the molecular and cellular processes that underlie the formation of new local and largescale brain circuits that support recovery from stroke.
Key points
• Stroke is the leading cause of complex adult disability in the world, but currently we do not provide a sufficient dose of the right physical or behavioural interventions to drive recovery • Clear lesion-induced changes occur in brain structure and function early after stroke, which result in an environment with unique heightened plasticity that can support restoration of function, termed spontaneous biological recovery • Intense, high-dose behavioural training aimed at the reduction of impairment and the restoration of function should be (but currently is not) delivered in this critical time window • The basis of spontaneous biological recovery in humans is unclear, which yields uncertainty over how and when to augment or prolong this process with novel therapies -further characterization is required to enable realistic phase III trials • Human neuroimaging techniques combined with modelling approaches can provide the appropriate biomarkers with which to map out a mechanistic approach to understand who and when to treat • The use of structural imaging to quantify damage in a range of brain regions can help predict long-term outcomes and provide the basis for stratification in restorative trials Nature Reviews | Neurology These studies are well described elsewhere [21] [22] [23] [24] [25] . Briefly, the basic elements of neural repair that can be seen in animal models of stroke include axonal sprouting, dendritic branching, synaptogenesis, neurogenesis and gliogenesis, and all can be increased in the early poststroke period. These events seem to occur in brain regions connected to the damaged area, including peri-infarct, ipsilesional and contralesional brain and spinal cord networks. Not all sprouting is clinically beneficial, and only axonal sprouting that links functionally related brain areas is consistently associated with improved poststroke outcomes 26 . Definitive evidence of these restorative processes in humans is scarce, but markers suggestive of neurogenesis 27 , gliogenesis 28 and axonal sprouting 27 have been found in human poststroke perilesional brain tissue. Consequently, the occurrence of similar biological responses to brain injury in both animals and humans seems probable. The precise temporal and spatial ordering of these poststroke biological events is governed by alterations in gene expression. Researchers have often remarked that the biological environment of the poststroke brain resembles that of the developing brain, and that 'recovery recapitulates ontogeny' (REF. 23 ). However, a clear distinction between regenerative and developmental transcriptomes has been shown, which indicates a unique regenerative molecular program at work 29 . Furthermore, expression of the regenerative transcriptome is strongly influenced by age at stroke onset, with earlier induction of growth-inhibiting molecules and later expression of growth-promoting molecules exhibited by older animals than by younger animals 30 . Preclinical work has attempted to both promote neuronal growth (BOX 1) and, most commonly, block extracellular inhibitory signals that counteract growth
, with some success 24, 31 . Changes to the structure of brain networks will not independently restore function, and all of these studies stress the need for appropriate levels of behavioural training, something that is often omitted from preclinical studies in animal models. The potential to form new functionally relevant circuitry that can be shaped by behavioural training provides a compelling mechanistic framework for functional recovery after stroke. However, the timing of administration of growth-promoting compounds, both in relation to the initial stroke damage and to the behavioural training itself, will clearly have a major effect on the thera peutic capacity. Whether training is delivered at the same time as growth-promoting molecules or sequentially could influence the type of sprouting that occurs and, consequently, whether behaviour is helped or hindered 32 . In addition, the effect that poststroke behaviour can have on restorative processes themselves is important to understand. For example, early compensatory use of the contralesional forelimb impairs recovery of the affected limb 33 , possibly through aberrant synapto genesis in the perilesional cortex 34 . Any behaviour, if overtrained, will take advantage of the increased poststroke potential for experience-dependent plasticity, and so abnormal or compensatory patterns of behaviour can become learned. Once again, this finding highlights the need for an appropriate form of behavioural training that can take advantage of any spontaneous or therapeutically enhanced potential for plasticity.
As well as asking 'when' treatment should be administered, 'where' is probably an equally important question. Most of the compounds discussed have been administered via intravenous or intrathecal routes, but accurate spatial and temporal delivery might be necessary to achieve the desired outcomes. Advances made in the past few years in tissue engineering 35, 36 and optogenetics 37 provide potential methods for precisely delivering regenerative molecules to functionally relevant brain regions.
Functional plasticity after stroke Identification of the trigger for poststroke regenerative processes could provide further therapeutic opportunities. In addition to the structural changes described above, focal brain damage results in alterations in neuronal excitability 38 . Immediately after stroke, signalling by the excitatory neurotransmitter glutamate is excitotoxic and contributes to cell death, whereas signalling by the inhibitory neurotransmitter GABA can counteract this toxicity through cell hyperpolarization 39 . This period lasts about 3 days poststroke in the mouse 40 and for an uncertain time in humans, after which the beneficial and detrimental effects of GABA and glutamate signalling seem to reverse. Specifically, changes to the cortical excitatory-inhibitory balance have long been known to influence the potential for experiencedependent plasticity in the cortex and can reopen critical periods of plasticity in the adult brain 41 . Reduced inhibitory tone can lead to facilitation of downstream changes in neuronal structure 42 , and one possibility is that the altered levels of neuronal activity that result from a change in excitability regulate neurogenesis and the activity of growth factors, such as brain-derived neurotrophic factor (BDNF), through epigenetic mechanisms 43 . Reduced cortical inhibitory mechanisms can lead to expanded and less-specific receptive fields 44, 45 , enhanced long-term potentiation 46 and remapping of sensorimotor functions to surviving cortex 47 in both hemispheres 48 , all of which is potentially useful when functional reorganization of brain structures poststroke is important for recovery of normal function. An altered balance between inhibitory GABAergic and excitatory glutamatergic signalling in surviving stroke regions and networks could, therefore, be a key event that sets other restorative mechanisms in motion.
In 2009, Murphy and Corbett 21 proposed that after the acute stroke period, attenuation of neuronal activity in brain regions connected to the damaged region might be reversed by a homeostatic increase in neuronal excitability, a process that can last at least several weeks 21 . Levels of neuronal excitability are determined by the balance in activity between GABA and glutamate, both of which are known to be altered after stroke 38 . For example, enhanced glutamate signalling through AMPA receptors, the major excitatory signalling system in the adult brain, is associated with improved recovery in mouse models of stroke 49 . This effect is probably due to downstream induction of BDNF 49 , which once again links altered neuronal excitability with downstream changes in axonal structure 50 . Much work on GABAergic signalling after stroke has focused on the reduction in phasic (that is, synaptic) inhibition in the first few weeks after injury 51 to increase the likelihood of long-term potentiation 46 . Specifically, GABA A receptors are dowregulated 48, 52 , and the density of several inhibitory interneurons is reduced after focal brain damage 44, 53 . Both increased glutamatergic signalling and reduced phasic GABAergic signalling would be consistent with the idea of a homeostatic restitution of neuronal activity 21 . However, two studies have suggested that increased perilesional tonic inhibitory signalling via extrasynaptic GABA A receptors might be the dominant response to stroke 40, 54 . When this tonic inhibition was reversed (using an α5 subunit that contained an extrasynaptic GABA A receptor inverse agonist) motor outcomes improved in both mouse 40 and rat 51 models of stroke. Although the increase in extracellular GABA in response to cerebral ischaemia is transient, the increase in tonic inhibitory signalling can persist for more than 1 month 38 , making this therapeutic window attractive compared with the window available for reperfusion strategies.
The interactions between excitatory pyramidal cells and numerous inhibitory interneurons in the cortex is clearly complex and becomes more complex after stroke 55 . In addition, prolonged ischaemia affects different cell types unequally 56 and causes alterations in the distribution of receptor subtypes 57 . The numbers of inhibitory interneurons (some of which inhibit other inhibitory interneurons) and pyramidal cells, as well as the ratios of receptor subtypes in the surviving cortex are not only unclear, but can differ between individuals. Nevertheless, the weight of evidence from animal studies to date suggests that spontaneous biological recovery is either augmented by a homeostatic restitution of cortical activity secondary to reduced phasic GABAergic inhibitory signalling, or blocked by excessive tonic GABAergic inhibitory signalling. Beyond the hyperacute period (up to 3 days poststroke in mice), the reversal in the beneficial and detrimental effects of GABA and glutamate signalling suggests that alterations in cortical inhibitory and excitatory mechanisms are important to determine the potential for plasticity and downstream structural changes that support recovery. Consequently, components of these inhibitory and excitatory mechanisms represent exciting and novel therapeutic targets for enhancing behavioural training after stroke.
As with mechanisms of structural plasticity, the mechanisms responsible for the alterations in cortical excitatory-inhibitory balance that underlie changes in poststroke functional plasticity are amenable to pharmacological and nonpharmcological manipulation. The most popular nonpharmacological approach is the use of noninvasive brain stimulation, which can enhance the effects of behavioural training to a small degree 58, 59 . In a mouse model, direct current stimulation to the brain augmented synaptic plasticity through BDNF dependent mechanisms 60 . However, in human studies, how much or how accurately electrical current is delivered to target brain regions is not clear, and consequently the results are inconsistent and the potential mechanisms are poorly understood 61, 62 . When it comes to pharmacological manipulation, tonic inhibition can be reversed by antagonists or inverse agonists of the α5-subunit-containing extrasynaptic GABA A receptor, and compounds for use in humans are currently available and under investigation in phase I studies. Zolpidem is an interesting pharmacological agent that binds with high affinity to α1-containing GABA A receptors, through which it mediates Box 1 | Promotion of neuronal growth Inosine Evidence indicates that the naturally occurring purine nucleoside inosine increases axon growth and improves outcomes in a preclinical model of stroke. Inosine promotes axonal collateral sprouting into areas that have lost their normal innervation, such as the corticospinal tract after stroke 142 or hippocampus after experimental traumatic brain injury 143 . Furthermore, inosine can augment the effects of anti-NogoA antibody (BOX 2) to restore skilled forelimb use after stroke 144 .
Growth and differentiating factor 10 (GDF10)
The gene encoding GDF10 is highly upregulated in the axonal regenerative transcriptome induced in peri-infarct neurons and promotes functionally useful axonal sprouting 145 .
Stem cells
Increasingly, interest has been shown in the use of stem cell therapy to promote recovery after stroke 146 . The two main lines of stem cell therapies are endogenous (promoting the production of existing neural stem cells) or exogenous (transplanted from another source) 147 . Over the past few years, research has explored how to reprogram adult human somatic cells to induced pluripotent stem cells, thereby producing patient-specific cells for autologous transplantation 148 . Rather than restoring lost tissue, stem cells could act as stimulants for trophic factors and modulators of immunological and inflammatory changes after stroke. Trials of exogenous cells in humans have proved safe, and claims have been made that the treatment improves clinical outcomes in patients with chronic stroke 149, 150 .
sedative and hypnotic effects. However, zolpidem can also influence tonic inhibition through α5-containing GABA A receptors in a dose-dependent manner, such that low levels of the drug augment tonic inhibition, and high levels reduce it 63 . Zolpidem can improve recovery in a mouse model of stroke 64 , and has been reported to mediate interesting effects, such as the temporary reversal of deficits in language, cognitive and motor function, in single patients with stroke 65, 66 . However, given the uncertainty over how zolpidem works, the mechanism of recovery in these individuals remains unclear.
The idea that pharmacological approaches can promote recovery of function after stroke has existed for decades (BOX 3) and has been well described 67 . Modulation of several neurotransmitter systems has had positive effects in animal models of stroke, usually correlating with their effect on long-term potentiation 67 . A key message from this early work is that close temporal coupling of the drug and the behavioural training is required for maximum therapeutic effect, which suggests that the therapeutic mechanisms are short-lived and reversible, rather than due to chronic effects. This point has not always translated into study design, but should be considered when interpreting the results of a pharmacotherapy study.
The fluoxetine for motor recovery after acute ischemic stroke (FLAME) study 68 has generated interest in selective serotonin reuptake inhibitors (SSRIs) as a therapy in stroke. In this study, 20 mg fluoxetine daily, started 5-10 days after ischaemic stroke and continued for 3 months, improved upper-limb motor recovery 68 . Many smaller studies of SSRIs have produced similar findings, but heterogeneity between studies is high 69 . Although SSRIs can influence structural plasticity, compelling evidence supports a plasticitymodifying effect mediated through the GABAergic system. Chronic doses of fluoxetine can reinstate critical-period plasticity in adult rats through a reduction of extracellular levels of GABA and an increase in BDNF expression 70 . Furthermore, Ng and colleagues 71 showed that, in a mouse model of stroke, fluoxetine treatment was able to prolong (but not reinstate) the critical period of poststroke plasticity through the reduction of inhibitory interneuron expression in the intact cortex 71 . Serotonin can have inhibitory (via 5HT 1A receptors) or facilitatory (via 5HT 2A receptors) effects on pyramidal cells, but most fast-spiking inhibitory interneurons are inhibited by serotonin through 5HT 1A receptors 72 . However, in the hippocampus, fluoxetine reduces fast-spiking inhibitory interneuron activity, which reduces gamma oscillations, independently of its action on mono amines 73 . In the cortex, chronic fluoxetine administration induces a reduction in layer II-III inhibitory interneuron activity; this reduction facilitates experience-driven structural dendritic remodelling 42 . A separate study in human primary motor cortex slices demonstrated that fluoxetine-induced reduction of inhibitory tone comes about through suppression of layer II-III monosynaptic excitatory connections from pyramidal cells to inhibitory interneurons, which leaves the monosynaptic output of GABAergic cells unaffected 74 . This layer-specific effect of fluoxetine is interesting in the context of work that demonstrates early poststroke 'enriched rehabilitation' to be more effective than environmental enrichment or reach training alone as a result of increased use-dependent plasticity in peri-infarct layer II-III cortex 75 . One possibility is that fluoxetine (and other pharmacotherapies) might influence training outcomes by replicating the biological effects of enriched environments.
Translation: animals to humans and back How can this work be translated from animal studies into patients with stroke? Opportunities undoubtedly exist for further understanding the biology that underlies regeneration and recovery after stroke by addressing some of the shortcomings of preclinical models with, for example, development of biological connectome-style mapping of large-scale axonal, dendritic and synaptic changes, increased use of subcortical white-matter models of stroke, and use of old animals. However, unidirectional translation from preclinical work has not led to dramatic improvements in human stroke recovery. Understanding the biological basis of recovery in humans by navigating the translational pipeline in a bidirectional and iterative manner 76 is consequently an urgent priority, because opportunities to augment or prolong spontaneous biological recovery would radically alter our understanding of how and when to best promote recovery after stroke. Establishing the nature and duration of a poststroke critical period in humans 
Myelin-associated proteins
Myelin-associated proteins such as Reticulon4 (also known as NogoA), myelin-associated glycoprotein (MAG), and myelin-associated oligodendrocyte basic protein have been shown to block neuronal regeneration. An anti-NogoA antibody has been used in preclinical models both of stroke and of spinal cord injury, and leads to improved recovery profiles. Sprouting is often seen across the midline, either at the level of brain stem or spinal cord. Lindau and colleagues 151 found that rats treated with anti-NogoA antibody recovered motor control after sensorimotor cortex ablation because intact corticospinal tract had extensively sprouted across the midline into the denervated spinal hemicord, which led to a somatotopic anatomical and functional side switch in the projection of adult corticospinal neurons. The safety of anti-NogoA antibodies has been tested in patients with spinal cord injury 24 and amyotrophic lateral sclerosis 152 , and anti-MAG has been tested in patients with stroke 153 .
Extracellular matrix proteins
Chondroitin sulfate proteoglycans mediate the inhibitory properties of perineuronal nets and are known to block axon growth. Cortical infarcts lead to a reduced density of perineuronal nets in peri-infarct cortex, which is maximal at 30 days post-lesion 44 . The enzyme chondroitinase ABC can reinstate critical period plasticity via the inactivation of chondroitin sulfate proteoglycans and therefore perineuronal nets 154 . In a rat model of stroke, chondroitinase ABC helped restore motor function after both acute and delayed administration 155 . However, extracellular matrix proteins are not always inhibitory, for example, the prevention of astrocytic scar formation can reduce stimulated axon regrowth 156 .
Growth cone inhibitors
Neuronal regeneration can also be inhibited by molecules that inhibit the axonal growth cone, such as semaphorins and ephrins. Ephrin-A5 is induced in astrocytes in peri-infarct cortex, which leads to inhibition of axonal sprouting. When ephrin-A5 signalling is blocked, motor training is more likely to promote recovery 157 . In this case, sprouting leads to a new pattern of reparative axonal projections in motor-related cortices of the ipsilesional hemisphere.
Neuronal oscillations
Rhythmic fluctuations in activity generated by neural tissue in the CNS either spontaneously or in response to stimuli; entrained oscillations in multiple neurons and neural networks are thought to form a critical interface between cellular activity and large-scale functions in the CNS.
Cortical microcircuits
Patterns of connections between specific excitatory and inhibitory neurons in the cortex.
is a crucial first step. The questions of whether hyperexcitability or hypoexcitability dominate in the poststroke period, how long these changes last and whether all patients have the same response all remain to be answered (FIG. 2) . Put simply, for any given therapy, we should know whether the aim is to prolong or reinstate the critical period provided by spontaneous biological recovery, or both. We currently have a lack of coherence between the preclinical and human accounts of poststroke recovery mechanisms (owing to our inability to examine humans on a cellular level as we can in pre clinical models), which is a barrier to translational work in the recovery field. Clinical trials of plast icitymodifying interventions in patients after stroke are currently being implemented without biological targets, which makes treatment of the appropriate patients at the best time almost impossible. Rational therapies require mechanistic approaches, without which largescale phase III randomized controlled trials of plasticitymodifying interventions are unlikely to succeed 77 . Animal studies of structural plasticity enhancement suggest that successful outcomes result from new local and large-scale connectivity. In patients, diffusion tensor imaging can be used to examine large white matter tracts after a stroke 78, 79 , but cannot be used to examine axonal terminal fields, where a number of important poststroke changes take place, owing to insufficient resolution. However, new anatomical connections should bring with them changes in poststroke functional brain architecture. Functional brain imaging can detect differences in task-related activation patterns that alter with time since stroke onset 80, 81 and the degree of impairment [82] [83] [84] . In addition, connectivity patterns after stroke can be assessed either at rest 85 or during an activity 86 , and these patterns might reflect the combination of new local and large-scale connectivity that is seen in animal models 87 . However, as yet, human neuroimaging has not been used to convincingly demonstrate the efficacy of therapies that aim to promote structural plasticity.
Alterations in cortical excitation and inhibition can influence outcome after stroke in animal models and consequently represent exciting and novel therapeutic targets. Use of transcranial magnetic stimulation 88 , magnetic resonance spectroscopy 89 and PET 90 in humans has provided support for the idea that GABAergic mechanisms are involved in stroke recovery but have not resolved the questions posed by work in preclinical models, including the timescale of changes in cortical excitability, whether hyperexcitability or hypoexcitability predominates (or whether they occur sequentially), and whether all patients have the same response. Without answering these questions, designing an effective clinical trial to test any therapeutic intervention that claims to interact with these biological processes is difficult. For example, determining when an α5-subunitcontaining extrasynaptic GABA A receptor agonist, fluoxetine or noninvasive brain stimulation should be used, and which patients are most likely to respond, requires an appropriate biomarker with which to reconcile animal and human accounts of poststroke recovery 91 . To be truly useful, a biomarker will link observed behaviour to unseen biological phenomena in order to make meaningful mechanistic inferences about that behaviour 92 . In the example of patients with severe upper limb impairment very early after stroke, we have discussed how the observed behaviour (initial impairment) dissociates from the subsequent recovery pathway. We would, therefore, hope to be able to identify underlying biological phenomena that predict recovery in a way that observed behaviour cannot, to ask whether failure of recovery is due to failure of the mechanisms underlying spontaneous biological recovery.
Several tools have been used in humans in attempts to identify the appropriate biomarker, but most have considerable limitations. For example, transcranial magnetic stimulation depends on the presence of evoked potentials in affected muscles, and bloodoxygen-level-dependent functional MRI relies on intact neurovascular coupling, limitations that effectively rule out the use of these tools in a large proportion of the patients that we need to study. Magnetic resonance spectroscopy can detect GABA, but the majority of the signal is probably from intracellular, rather than synaptic or extrasynaptic, GABA. PET can assess GABA A activity 90, 93 using flumazenil, but this activity probably reflects cerebral hypoperfusion and neuronal density and integrity 94 rather than cortical excitability per se. Consequently, interest in the use of neuronal oscillations as biomarkers of the potential for activity-dependent plasticity after stroke is growing 91, 95, 96 . Neuronal oscillations can be measured noninvasively with magnetoencephalography (MEG) or electroencephalography, which detect the magnetic or electrical fields generated by neuronal activity of the brain 97 . Specifically, MEG measures the summation of postsynaptic fields from pyramidal cells 98 with excitatory glutamatergic projections, which are reciprocally connected to interneurons with inhibitory GABAergic projections. MEG signals are, therefore, dependent on the interaction between inhibition and excitation within cortical microcircuits 99 . For example, resting beta band (15-30Hz) power is enhanced by GABAergic signalling 99, 100 . Furthermore, typical movement-related beta desynchronization is enhanced by phasic and tonic inhibition, but post-movement beta rebound is enhanced only by tonic The idea of pharmacotherapy for stroke recovery is not recent. Early work in this field was performed in 1963 by Alexander Luria and colleagues, who studied soldiers with head injuries 158 . Luria et al. proposed that symptoms could be induced by functional inhibition of intact neurons in addition to cell death, and that "removal of the diaschisis, restoration of synaptic conduction or to use another term, 'deblocking'" might be helpful 159 . The investigators proposed that this task could be achieved by the combination of two approaches. First, the administration of a pharmacological agent (generally anticholinesterases) "capable of removing inhibition, modifying mediator metabolism and restoring disturbed synaptic conduction" (REF. 159 ), and second, by methods of training which promote 'deblocking', the essence of which is "that by means of various methods the level of excitability in certain functional systems is raised and the corresponding functions are 'de-inhibited'" (REF. 159 ). The general concepts have a similar ring to current concepts; although the underlying mechanisms might now be more apparent than in the past, the clinical outcomes have not advanced a great deal. Poststroke plasticity and excitability
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Computational neurorehabilitation
A newly emerging field aimed at mathematical modelling of plasticity and learning to understand and improve recovery of individuals with neurological impairment. inhibition 101, 102 . These neuronal oscillations are highly reproducible within individuals 103 and could serve as appropriate longitudinal biomarkers of net inhibitory and excitatory mechanisms in human cortex after stroke and enable differentiation between the contribution of phasic and tonic inhibition to the measured signal, thereby providing a window into the mechanisms of activity-dependent plasticity that are important for recovery.
The utility of neuronal oscillations as biomarkers of plasticity mechanisms after stroke is further supported by a number of findings. First, poor outcomes of stroke are associated with a persistent increase in low-frequency oscillations 104 , similar to those caused by benzo diazepines (GABA A -agonists that cause phasic inhibition) and tiagabine (a GABA reuptake inhibitor that induces in tonic inhibition) [100] [101] [102] , which suggests that inhibitory mechanisms predominate in the peril esional cortex, and impair recovery. Second, a low beta-rebound response to tactile finger stimulation (which indicates increased early poststroke sensori motor excitability 105 and increased sensory map size 106 ) predicts a good recovery in patients with stroke, as in animal models 21 . Last, in a single patient with stroke, zolpidem reversed the increases in perilesional theta (4-10Hz) and beta oscillations and led to clinical improvement 66 . Zolpidem is pharmacologically interesting in that it has dose-dependent effects on both phasic and tonic GABAergic signalling. The key aspect in this result is that, regardless of how zolpidem was acting, the change in neuronal oscillations matched the clinical improvement, which highlights the potential of neuronal oscillations as biomarkers of cortical excitatory-inhibitory balance.
Some have argued that a fundamental understanding of poststroke recovery requires the development of computational models of the salient neural processes, including plasticity and learning systems of the brain 107 . This understanding would enable models of under lying biological phenomena to be linked to appropriate behavioural processes. A particular advantage of MEG for this computational neurorehabilitation approach is that the high temporal resolution of the spectral data lends itself to the use of biophysical models. Consequently, mechanistic inferences about poststroke changes in oscillations can be made at both intracortical (mesoscopic) and network (macroscopic) levels. The model features are neurobiologically motivated 108, 109 so results offer a mechanistically meaningful interpretation at different scales of brain architecture. At the macroscopic level, stroke disrupts functional connections in the peri-infarct region and remotely connected regions, so investigation of brainwide network dynamics is important during poststroke recovery 110 . Modelling of MEG data enables inferences at the cortical network level 111 and the assessment of both inhibitory and (separately) excitatory effective coupling between cortical motor regions at the same frequency (that is, linear coupling; for example, beta to beta) and different frequencies (that is, nonlinear coupling; for example beta to gamma). This assessment is useful, as nonlinear coupling is important for functional integration across the brain and could reflect altered structural connec tivity across networks that support recovery. Interestingly, inferences can also be made at the cortical microcircuit level 108 . This novel mathematical modelling approach has been validated using local field potentials in mouse models, where independent pharmacological and microdialysis assays corroborated the modelling results 109 . For example, a novel biophysical model of human primary motor cortex 112 has been developed to reproduce key neurophysiological characteristics of mouse primary motor cortex 113 . In this model, parameters represent either the strength of connections between pyramidal cells and inhibitory interneurons, or the overall excitability in each population of cells 114 . Ultimately, the combination of both scales within a single generative model framework will be possible, to enable construction of a comprehensive model of poststroke functional architecture. This type of model can also be applied to local field potential data 109 , providing a way to directly compare -and consequently validate -recovery mechanisms in future studies in animal models and humans to develop a mechanistic understanding of recovery in humans.
Rehabilitation
The reason for wanting to understand how to optimize the poststroke brain environment is to maximize the effect of behavioural training, which can take the form of physical, cognitive or speech therapy. The presence of a critical period of plasticity advocates for Evidence from animal models of stroke points to both (1) an upregulation of neuronal growth-promoting factors and an increase in neuronal excitability (blue area), both of which would create an environment that would encourage recovery of function, and (2) an upregulation of neuronal growth-inhibiting factors and an decrease in neuronal excitability (red area) both of which would create an environment that would limit recovery of function. Whether these processes occur after stroke in humans is unknown. Further work is required to determine which of these processes predominates, how long each one lasts, and whether the same processes occur in all patients to the same degree. This knowledge is crucial for determining the optimal timing for the introduction of both behavioural and plasticity-enhancing treatments.
the delivery of high-dose and high-intensity behavioural training during this window of opportunity to maximize recovery of function by minimizing impairment 18 . For the upper limb, trials of intensive training that commence before 3 months after stroke still provide only modest amounts of therapy, and the effect sizes range from minimal to modest [115] [116] [117] . One small study in which training started 2-4 weeks after stroke did find that an extra 90 h of upper limb training (3 h per day for 6 weeks) increased the upper limb Fugl-Meyer score (a reasonable assessment of motor impairment) by a clinically meaningful extra 12 points compared with those receiving an extra 30 h 118 . Trials in patients with chronic stroke (>6 months since stroke onset) have generally involved up to 30 h of additional therapy, usually at 1 h per day, but have not had dramatic effects on impairment [119] [120] [121] . However, one study involved 300 h of various upper-limb therapies over 12 weeks for patients with chronic stroke, and resulted in comparatively large reductions in impairment: 11 points on the Fugl-Meyer scale 122 . Similar changes have been reported in a study of a single-centre service that involved 90 h of high-dose upper-limb therapy over 3 weeks 123 . The number of hours of therapy also has a clear effect on aphasia: studies with positive outcomes have involved a mean of 98.4 h of treatment, whereas studies with negative outcomes have involved a mean of 43.6 h 124 . Whether equivalent doses of therapy have an increased effect on impairment if delivered in the early rather than late poststroke phase is not yet clear.
Much has been written about what form of behavioural training should be used, how it should be scheduled and what method of delivery is optimal 6 . However, as illustrated by the proportional recovery rule, these deliberations are not currently affecting outcomes at the level of impairment -at least, not in the motor domain 125 . The currently used dose and intensity of rehabilitation after stroke is probably too low 126, 127 , and an increase in both dose and intensity using an appropriate training approach could lead to the large effect sizes that patients and clinicians want to see. Parallels can be drawn with data from animal studies demonstrating that the number of reaches made by an animal must exceed a certain threshold before an effect on poststroke outcomes is observed 128 . The amount of therapy (particularly the amount of time on task) has been shown to have a positive influence on outcomes 129 , but these findings are not currently influencing clinical practice.
A key question is whether the lack of a dramatic effect is due to biological factors -in which case, have we already reached the limit of achiev able improvements? Alternatively, are we simply not providing enough treatment (at least, not of the correct type or at the right time) or not using the most advantageous combinations of treatment? The use of aspirational approaches to investigate what is possible rather than what is pragmatic is vitally important. Current studies tend only to investigate interventions that could be delivered in current health care systems.
Only knowledge of the true limits of recovery after stroke, in both the early and chronic phase, will enable the design of an appropriate clinical service to achieve maximal recovery in an efficient and cost-effective way. Currently, the resources to deliver intensive early rehabilitation are scarce, and are virtually nonexistent for patients with chronic stroke. In the 1990s, the same was true of acute stroke services, but clinical trials of thrombolysis demonstrated improvements in outcome for patients with stroke so compelling 130 that the way acute stroke care was delivered had to be radically altered to accommodate this new knowledge. In effect, stroke recovery programs need a 'thrombolysis moment' , which will only come about through aspirational rather than pragmatic approaches.
Future predictions
The ability to accurately predict long-term clinical outcomes in patients after stroke is important for a number of reasons. First, outcome prediction is useful to plan treatments and to set goals in a rehabilitation program. Second, these predictions will enable clinical trials of restorative treatments to be conducted in which patients are stratified into control and treatment groups on the basis of expected outcome, without the requirement for extremely large numbers of patients 131 . Third, predictions of long-term outcomes in response to current treatment approaches could become the new benchmark with which to judge novel treatment approaches. In other words, the goal of any new intervention might be to deliver an outcome better than currently predicted, either at an individual or group level.
Currently, the best predictor of long-term outcome -certainly in the motor domain -is initial severity. The limitations of initial severity as an outcome predictor are reflected in the proportional recovery rule, which fails in about half of patients with stroke who present with initially severe impairment 14 . Understanding why these patients do not recover as well as others with equally severe initial impairments will not only improve predictive models of long-term outcome, but will reveal the factors that are important for the recovery process itself. As discussed in previous sections, measures to investigate the mechanisms of poststroke plasticity in patients after a stroke might be usefully incorporated into a predictive model for long-term outcome. Small-scale approaches have shown how functional imaging data can readily be incorporated into these models 132, 133 . Any attempt to predict long-term outcome must take into account damage to key brain regions (FIG. 3) . For example, optimal recovery of movement after stroke requires preservation of anatomical structures that convey sensory signals to the brain, and those that convey motor commands out of the brain, so that behavioural interventions can drive remapping of sensorimotor functions in surviving brain areas and networks 21 . Indeed, in humans, more extensive corticospinal tract (CST) damage causes greater upper limb impairment 134 ; although CST damage correlates with initial upper limb impairment, it can account for some proportion of upper limb outcome over and above that predicted by initial severity 15, 135 . Most of this work has been carried out in patients with subcortical strokes, so the effect of damage to widespread cortical areas -especially those required for cognitive functions that are important for learning, such as memory and sustained attention -has not been assessed. Quantification of damage within CST is poor at accounting for impairment in patients with infarcts involving both subcortical and cortical areas (FIG. 3) 136 . In fact, a combination of cortical motor areas and CST is the most accurate way to account for upper limb motor impairment in a wide range of patients with stroke who have infarcts that involve sub cortical and/or cortical regions 137 . In the language domain, the Predicting Language Outcome and Recovery After Stroke (PLORAS) system 138 demonstrates that, when using similar machine-learning approaches, the individual trajectory of language recovery can be predicted from structural brain scans.
Whether the addition of information about residual functional architecture to predictive models of stroke will provide independently useful predictive information remains to be seen. In the motor domain, most findings indicate a decreased resting connec tivity between primary motor cortices in patients who have high motor impairment 139 and severe corticospinal tract damage 140 . During movement of the affected hand, the influence of contralesional to ipsilesional primary motor cortex is more inhibitory than normal, but once again, only in patients who have high motor impairment 86 . In one study that examined a number of demographic, genetic and brain imaging characteristics of patients with chronic stroke who underwent 3 weeks of upper limb robotic training, low CST damage, absence of cortical damage and increased connectivity between primary motor cortices were factors that indicated an increased chance of clinical improvement 141 . The incorporation of information about brain structure and function together with readily available clinical information should provide the optimal approach to develop new models that predict long-term outcome after stroke. The size of databases containing this information now needs to increase to maximize the precision with which predictions can be made, because predictive accuracy is likely to be important in determining patient and clinician uptake in using this information.
Conclusions
Great advances have been made in understanding the biological basis of neurological functional restoration after stroke. However, translation into human studies has been slow. Two key elements promote optimal restoration of function after stroke: effective behavioural training that targets impairment as well as function, and treatments that can augment and/or prolong plasticity in the poststroke critical period of plasticity. Current implementation of new treatments to promote recovery (such as drugs and noninvasive brain stimulation) in phase III trials lacks a clear mechanistic rationale and is, therefore, premature 77 . To achieve progress, mechanistic studies to understand poststroke mechanisms of plasticity must move into humans with stroke, and future investigation in the translational pipeline must become bi directional and iterative 76, 92 . Effective behavioural therapies and appropriate biomarkers of poststroke plasticity mechanisms are both desperately needed to help understand Figure 3 | Characterization of anatomical damage. a | Brain maps derived from patients with chronic stroke caused by damage to subcortical brain regions ('subcortical') with or without extension to the cortex ('cortical'). The colour scale represents the voxel-wise 'impairment weighting', i.e. the contribution that damage in a brain area is likely to make to motor impairment. Blue represents the areas where damage is highly likely to cause motor impairment: these areas extend into cortical regions for the 'cortical' patients. Analysis was performed using a multivoxel pattern analysis tool PRoNTo. b | The mean impairment weightings for four different regions of interest in patients with cortical or subcortical stroke damage. Whereas damage within corticospinal tract accounted for impairment in the subcortical group (red asterisk), damage in sensorimotor areas accounted for more impairment in the cortical group (blue asterisk) 136 . Damage in a whole brain mask of white matter and grey matter contributed to impairment in patients with cortical but not subcortical stroke damage. c | A brain map of cortical and subcortical brain regions important for sensorimotor function (colours represent different anatomical regions from the automated anatomical labelling atlas), together with a corticospinal tract map 78 . d | A machine-learning regression approach showed that damage to voxels contained in the map in part c accounted for 68% of motor impairment in 50 patients with chronic stroke, as illustrated in the graph of predicted motor impairment plotted against real motor impairment in these patients. The same analysis using only the corticospinal tract region of interest accounted for only 42% of the motor impairment, suggesting that knowledge of damage to a range of motor related brain structures, not just corticospinal tract, is important for predicting outcome who and when to treat, and the methodologies to achieve these aims are now readily available. This information must lead to a step-change in how restorative treatments for stroke are delivered. Clinical trial design must take account of the biological mechanisms underlying stroke and should stratify different patient subpopulations, rather than using a 'one size fits all' approach. Attempts to treat impairment in chronic stroke have been disappointing and have not produced the dramatic effect sizes required to transform the field 76 . Targeting the mechanisms that underlie early spontaneous biological recovery in humans represents the most promising path to dramatically improve patients' outcomes 18 and should be prioritized. However, the limits of what is possible in chronic stroke have not yet been explored, especially if the delivery of high doses of behavioural therapy in reopened critical periods of plasticity becomes possible.
